Name: Feifei Pu

Country: China

Affiliation:

Department of Orthopedics, Wuhan No.1 Hospital, Wuhan Integrated TCM & Western Medicine Hospital, Tongji Medical College, Huazhong University of Science and Technology.

Phone no: 86-27-8533276, 86-15871755528

Email: Send an Email


Address:

No.215, Zhongshan Road, 
Qiaokou District, 
Wuhan, Hubei, 430022, 
China.

Research Interests:

  • Bone tumor 
  • Degenerative disease of bone and joint.

Biography:

1. Excellent thesis award of Chinese anti cancer association (CACA), the 9th China tumor academic conference.

2. New technology and new business achievement award, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology.

3. "Surgery Star" of Wuhan No.1 Hospital, Wuhan Integrated TCM & Western Medicine Hospital.

4. "Excellent PhD Graduates" of Huazhong University of Science and Technology.

1. Oral presentations in the 17th orthopedics academic conferences of Chinese medical association and the 10th international academic conference, COA.

2. Oral presentations inthe 17th national conference of bone tumors of Chinese medical association.

3. Posters inthe 18th orthopedics academic conferences of Chinese medical association and the 11th international academic conference, COA.

4. Posters in the 36th international orthopaedic and trauma surgery society (SICOT). 5. Posters in the 9th China tumor academic conference

Publications:

  1. Pu F, Chen F, Chen S, Wang B, Liu J, Shao Z. Association between GSTP1 polymorphisms and prognosis of osteosarcoma in patients treated with chemotherapy: a meta-analysis. Onco Targets Ther. 2015; 8(7):1835-42.
  2. Pu F, Shao Z, Yang S, Liu J, Lin S, Ma X, Yang H. Association between functional variants in BIRC5/survivin gene 3' untranslated region and mRNA expression in lymphoblastoid cell lines. Oncol Lett, 2015,10(4):2319-22.
  3. Pu F, Chen F, Lin S, Chen S, Zhang Z, Wang B, Shao Z. The synergistic anticancer effect of cisplatin combined with Oldenlandia diffusa in osteosarcoma MG-63 cell line in vitro. Onco Targets Ther. 2016;9(1):255-63.
  4. Pu F, Chen F, Shao Z. MicroRNAs as Biomarkers in the diagnosis and treatment of chondrosarcoma. Tumor Biol. 2016;37(12): 15433-6.
  5. Pu F, Wang B, Liu J, Chen F, Shao Z. Giant chordoma in the thoracolumbar spine: a case report and literature review. Eur Spine J. 2017; 26(1):S95-9.
  6. Pu F, Chen F, Zhang Z, Feng J, Xia P. Functional variants of TIM-3/HAVCR2 3’UTRin lymphoblastoid cell lines. Future Sci. OA. 2018: FSO298.
  7. Pu F, Chen F, Zhang Z, Qing X, Lin H, Zhao L, Xia P, Shao Z. Expression of TIM-3 in primary osteosarcoma and its association with survival. Oncol Lett. (Accepted)
  8. Pu F, Shao Z. Advances in gene therapy for osteosarcoma. Int J Orthop (Chinese).2013, 34(3): 193-5.
  9. Pu F, Shao Z. Advances of T cell Immunoglobulin Mucin-3 in Tumor Immunity. Cancer Res Prev Treat (Chinese). 2017, 44(10): 701-5.
  10. Zhang Z, Pu F, Shao Z. The skeletal-related events of denosumab versus zoledronic acid in patients with bone metastases: a meta-analysis of randomized controlled trials. J Bone Oncol. 2017;9:21-4.